PEŠL, Martin, Jan PŘIBYL, Šimon KLIMOVIČ, Martin ŠČUREK, Deborah BECKEROVÁ, Kristián BRAT, Petr SKLÁDAL and Vladimír ROTREKL. Cell based AFM biosensensing for screening of pulmonary-drug related arrhytmic effects. Online. In Nanocon 2020. 2021st ed. Brno: TANGER Ltd., 2021, p. 404-409. ISBN 978-80-87294-98-7. Available from: https://dx.doi.org/10.37904/nanocon.2020.3745.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cell based AFM biosensensing for screening of pulmonary-drug related arrhytmic effects
Authors PEŠL, Martin (203 Czech Republic, guarantor, belonging to the institution), Jan PŘIBYL (203 Czech Republic, belonging to the institution), Šimon KLIMOVIČ (203 Czech Republic, belonging to the institution), Martin ŠČUREK (203 Czech Republic, belonging to the institution), Deborah BECKEROVÁ (203 Czech Republic, belonging to the institution), Kristián BRAT (703 Slovakia, belonging to the institution), Petr SKLÁDAL (203 Czech Republic, belonging to the institution) and Vladimír ROTREKL (203 Czech Republic, belonging to the institution).
Edition 2021. vyd. Brno, Nanocon 2020, p. 404-409, 6 pp. 2021.
Publisher TANGER Ltd.
Other information
Original language English
Type of outcome Proceedings paper
Field of Study 21001 Nano-materials
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Publication form electronic version available online
WWW URL
RIV identification code RIV/00216224:14110/21:00120083
Organization unit Faculty of Medicine
ISBN 978-80-87294-98-7
ISSN 2694-930X
Doi http://dx.doi.org/10.37904/nanocon.2020.3745
UT WoS 000664505500069
Keywords in English Cardiomyocyte; contraction; arrhythmia; in vitro modeling; drug adverse events; pulmonary drugs
Tags CF NANO, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/8/2023 08:02.
Abstract
Atomic force microscopy (AFM) combined with stem cell derived human cardiomyocytes (CM) enables dynamic follow-up of cardiac contractions (e.g. beating rate, contraction and relaxation times), simultaneously with other CM biomechanical properties. Today, majority of drugs entering clinical usage needs to be tested for adverse arrhythmic effects; nevertheless, the effects on cardiomyocyte contraction are not routinely employed, only when related to cardiac pathologies. AFM-based biosensor allows in-vitro disease modeling, but also enables to monitor the effect of CM-contraction affecting drugs. Until today only few selected drugs modulating contractility and spontaneous pacing were described in animal models. This work for the first time demonstrates that basic biomechanical parameters, such as average value of contraction force and the beat rate, represent valuable pharmacological indicators of different phenotypic effects on cells without genetic burden. The presented method is robust and has low computational requirements, while keeping optimal spatial sensitivity (force detection limit 200 pN, corresponding to 20 nm displacement). The cardiac stimulating activities of drugs utilized in pneumology as aminophylline, ipratropium, and salbutamol were tested. Stimulating drugs, e.g. methylxanthines and caffeine, presented aberrant cardiomyocyte response, confirming arrhythmogenic potential, and force related fluctuations. Quantification of spontaneous contraction irregularities and related contractility changes allow precise scaling of potential negative effects adding new safety level to clinically relevant drug testing. AFM combined with human CMs serve as robust real-time screening platform for effects of pulmonary drugs. Here we describe changes in CM contractility, which is hard to describe by other screening methods and was never tested with described medication.
Links
LM2018127, research and development projectName: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1455/2019, interní kód MUName: Arytmogenní efekt aminophyllinu na buněčné kultury kardiomyocytů
Investor: Masaryk University, Category A
NU20-06-00156, research and development projectName: Vliv pneumologické medikace na funkce lidských kardiomyocytů.
Investor: Ministry of Health of the CR, Subprogram 1 - standard
PrintDisplayed: 15/7/2024 00:33